Biocon Biologics, one of India's leading biologic drug manufacturers, announced on Friday the results of a Phase-3 study on a ...
Johnson & Johnson’s once-daily oral peptide has bested Bristol Myers Squibb’s reigning oral psoriasis med Sotyktu in a ...
Some patients with psoriasis may have a super response to guselkumab, but questions remain regarding the generalizability of treatment strategies.
Discover a study that concludes that the DermSat-7 is a valid and reliable instrument for measuring treatment satisfaction in ...
Patients treated with ESK-001 for moderate to severe plaque psoriasis experienced positive clinical responses through a year, ...
4d
Medpage Today on MSNHumira Copycats for Psoriasis Backed by Real-World OutcomesIn a cohort of more than 11,000 patients from the U.K. and Ireland, a comparable proportion of new adalimumab users achieved ...
Late-stage data also showed that Johnson & Johnson’s icotrokinra was superior to Bristol Myers Squibb’s Sotyktu at clearing ...
Standout combination of complete skin clearance and favorable safety profile in a once daily pill could shift treatment paradigm Nearly half of patients with moderate-to-severe ...
10d
Verywell Health on MSNUnderstanding Scalp Psoriasis and How to Treat ItScalp psoriasis can cause crusty patches or scales on the surface of the head. Find details about medicated shampoos, ...
SFA Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel oral small-molecule biosynthetic ...
Topline results from Phase 3 ICONIC-ADVANCE 1&2�studies show icotrokinra achieved co-primary endpoints and showed superiority to deucravacitinib in moderate-to-severe plaque PsO ...
Tildrakizumab showed early and sustained effectiveness and quality of life (QOL) improvements in patients with moderate to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results